[go: up one dir, main page]

MX2014002471A - Combinaciones sinergicas de los inhibidores de p13k y mek. - Google Patents

Combinaciones sinergicas de los inhibidores de p13k y mek.

Info

Publication number
MX2014002471A
MX2014002471A MX2014002471A MX2014002471A MX2014002471A MX 2014002471 A MX2014002471 A MX 2014002471A MX 2014002471 A MX2014002471 A MX 2014002471A MX 2014002471 A MX2014002471 A MX 2014002471A MX 2014002471 A MX2014002471 A MX 2014002471A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
pi3k
mek
combination
amide
Prior art date
Application number
MX2014002471A
Other languages
English (en)
Inventor
Christine Fritsch
Xizhong Huang
Markus Boehm
Emmanuelle Di Tomaso
Jan Gce Cosaert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014002471A publication Critical patent/MX2014002471A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una combinación farmacéutica que comprende (a) el compuesto inhibidor de fosfatidilinositol 3-cinasa (PI3K) 2-amida 1-({4-metil-5-[2-(2,2,2-trifluoro-1, 1-dimetil-etil)-piridin-4-il] -tiazol-2-il}-amida) del ácido (S)-pirrolidin-1 ,2-dicarboxílico o una sal farmacéuticamente aceptable del mismo, y (b) al menos un inhibidor de proteína cinasa activada por mitógenos (MEK) o una sal farmacéuticamente aceptable, y opcionalmente al menos un portador farmacéuticamente aceptable, para la administración simultánea, separada o secuencial; los usos de tal combinación en el tratamiento de enfermedades proliferativas; y métodos para el tratamiento de un sujeto que sufre de una enfermedad proliferativa que comprenden administrar una cantidad terapéuticamente efectiva de tal combinación.
MX2014002471A 2011-08-31 2012-08-30 Combinaciones sinergicas de los inhibidores de p13k y mek. MX2014002471A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529380P 2011-08-31 2011-08-31
US201161542463P 2011-10-03 2011-10-03
PCT/US2012/052955 WO2013066483A1 (en) 2011-08-31 2012-08-30 Synergistic combinations of pi3k- and mek-inhibitors

Publications (1)

Publication Number Publication Date
MX2014002471A true MX2014002471A (es) 2014-03-27

Family

ID=47720713

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002471A MX2014002471A (es) 2011-08-31 2012-08-30 Combinaciones sinergicas de los inhibidores de p13k y mek.

Country Status (11)

Country Link
US (1) US9675595B2 (es)
EP (1) EP2750675A1 (es)
JP (1) JP6058009B2 (es)
KR (1) KR20140072028A (es)
CN (1) CN103764144B (es)
AU (1) AU2012333092B2 (es)
BR (1) BR112014004587A2 (es)
CA (1) CA2846454A1 (es)
MX (1) MX2014002471A (es)
RU (1) RU2607944C2 (es)
WO (1) WO2013066483A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
MX347708B (es) 2011-01-10 2017-05-09 Infinity Pharmaceuticals Inc Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
CN105283180A (zh) * 2013-06-11 2016-01-27 诺华股份有限公司 Pi3k抑制剂与微管去稳定剂的药物组合
CN105338980A (zh) * 2013-06-18 2016-02-17 诺华股份有限公司 药物组合
US20160331755A1 (en) * 2014-01-15 2016-11-17 Samit Hirawat Pharmaceutical Combinations
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
EP3370775B1 (en) * 2015-11-03 2023-04-19 Genentech, Inc. Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
WO2020053125A1 (en) * 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
RU2192861C1 (ru) 2001-06-29 2002-11-20 Новосибирский институт биоорганической химии СО РАН Композиция для антибластической терапии
WO2003077914A1 (en) * 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PL2298768T3 (pl) 2004-06-11 2013-03-29 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EP1841431A4 (en) * 2005-01-26 2009-12-09 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
ES2378760T3 (es) * 2005-05-18 2012-04-17 Array Biopharma, Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PL2074122T3 (pl) 2006-09-15 2011-10-31 Pfizer Prod Inc Związki pirydo(2,3-D)pirymidynonowe i ich zastosowanie jako inhibitory PI3
KR20110028651A (ko) * 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
MX345155B (es) * 2009-10-12 2017-01-18 F Hoffmann-La Roche Ag * Combinaciones de un inhibidor de pi3k y un inhibidor de mek.

Also Published As

Publication number Publication date
AU2012333092B2 (en) 2016-04-21
CA2846454A1 (en) 2013-05-10
CN103764144A (zh) 2014-04-30
WO2013066483A1 (en) 2013-05-10
JP2014525454A (ja) 2014-09-29
RU2607944C2 (ru) 2017-01-11
RU2014112198A (ru) 2015-10-10
BR112014004587A2 (pt) 2017-03-14
US9675595B2 (en) 2017-06-13
JP6058009B2 (ja) 2017-01-11
CN103764144B (zh) 2016-07-20
US20140179744A1 (en) 2014-06-26
KR20140072028A (ko) 2014-06-12
AU2012333092A1 (en) 2014-03-06
EP2750675A1 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
MX2015017629A (es) Combinaciones farmaceuticas.
MX2015000746A (es) Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k).
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
JP2014525454A5 (es)
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
WO2007131168A3 (en) Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
WO2015097621A3 (en) Pharmaceutical combinations
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
HK1198869A1 (en) Combination treatments for hepatitis c
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
WO2007058990A3 (en) Therapy using cytokine inhibitors
IN2015DN00528A (es)
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
UA115250C2 (uk) Фармацевтичні комбінації
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
WO2015035410A8 (en) Cancer therapy
NZ628596A (en) Pharmaceutical diagnostics for treatment of cancer in subjects having pi3k mutation
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.